MAPK8 and liver cancer: Dehydroclatidine can induce cell cycle arrest in the G2/M phase, activate the apoptosis pathway mediated by mitochondria and death receptors, reduce the viability of liver cancer cells, and trigger apoptosis of liver cancer cells by inhibiting JNK1/2 phosphorylation (Velmurugan et al., 2022).